FUNDAMENTAL PARADIGMS IN CLINICAL PHARMACOLOGY: A DUAL PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC EVALUATION OF POLYPHARMACY IN CHRONIC METABOLIC DISORDERS

Abstract

The rapid proliferation of targeted therapeutics requires an evolution in clinical pharmacology, shifting the analytical focus from isolated pharmacokinetic parameters to comprehensive population-level dynamics. This manuscript presents an integrated empirical evaluation of the core disciplines of pharmacoepidemiology and pharmacoeconomics through a rigorous assessment of polypharmacy in type 2 diabetes mellitus accompanied by cardiovascular comorbidities. Utilizing a retrospective observational cohort design coupled with a probabilistic Markov decision model, the clinical trajectories of 2150 patients were tracked over a 36-month follow-up period. The investigation measured the real-world incidence of adverse drug reactions alongside a rigorous Cost-Utility Analysis from a healthcare system perspective. Pharmacoepidemiological surveillance revealed that patients receiving advanced sodium-glucose cotransporter-2 inhibitors exhibited a profoundly reduced risk of cardiovascular hospitalization compared to those on standard sulfonylurea-based regimens, reflecting a Relative Risk of 0.36 (95% CI: 0.28-0.45, p < 0.001). Concurrently, severe hypoglycemic events dropped from 4.8 to 1.1 per 100 patient-years. Translating these epidemiological safety outcomes into economic utility, the pharmacoeconomic modeling demonstrated that the advanced therapeutic cohort accumulated an average of 2.68 +/- 0.12 Quality-Adjusted Life Years against 2.21 +/- 0.18 in the standard care group. The resulting Incremental Cost-Effectiveness Ratio stood at USD 1425 per Quality-Adjusted Life Year gained. These findings mathematically validate that higher initial acquisition costs are entirely neutralized by the mitigation of severe clinical exacerbations. Integrating pharmacovigilance with health economics provides a mandatory quantitative foundation for rationalizing national formularies and optimizing value-based clinical decision-making.